Total Voting Rights

Ergomed

01/02/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230201:nRSA4694Oa&default-theme=true

RNS Number : 4694O  Ergomed plc  01 February 2023

 

Total Voting Rights

 

 

Guildford, UK - 1 February 2023: In accordance with the Financial Conduct
Authority's Disclosure Guidance and Transparency Rules ("DTRs"), Ergomed plc
(the "Company") announces the following information.

 

The Company's issued share capital as at 31 January 2023 consisted of
50,300,805 ordinary shares of 1p each, none of which were held in treasury.
Each ordinary share in the capital of the Company carries one voting right.

 

The above figure may be used by shareholders as the denominator for the
calculations by which they will determine if they are required to notify their
interest in, or a change to their interest in, the Company, under the DTRs.

 

ENDS

 

Enquiries:

 

Ergomed plc
                                        Tel: +44 (0) 1483
402 975

Dr Miroslav Reljanović (Executive Chairman)

Richard Barfield (Chief Financial Officer)

Jonathan Curtain (Deputy Chief Financial Officer)

Keith Byrne (Senior Vice-President, Capital Markets and

Strategy)

 

 

Numis  (Nominated Advisor and Joint Broker)
           Tel: +44 (0) 20 7260 1000

Freddie Barnfield / Euan Brown (Nominated Adviser)

James Black (Broker)

 

Peel Hunt LLP  (Joint Broker)
                          Tel: +44 (0) 20 7418 8900

James Steel / Dr Christopher Golden

 

Consilium Strategic Communications  - for UK enquiries          Tel: +44
(0) 20 3709 5700

Chris Gardner / Matthew Neal
 
ergomed@consilium-comms.com

 

 

 

 

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning
all phases of clinical development, post-approval pharmacovigilance and
medical information. Ergomed's fast-growing services business includes an
industry-leading suite of specialist pharmacovigilance (PV) solutions,
integrated under the PrimeVigilance brand, a full range of high-quality
clinical research and trial management services under the Ergomed brand (CRO)
and mission-critical regulatory compliance and consulting services under the
ADAMAS brand. For further information, visit: http://ergomedplc.com
(http://ergomedplc.com) .

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TVRBBMFTMTTJBIJ